AXIM BiotechnologiesAXIM -8.33% EV-to-EBIT is 40.25 as of Jul. 08, 2026. Among 365 Biotechnology companies, AXIM Biotechnologies ranks worse than 78.08% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
AXIM Biotechnologies's Enterprise Value for the quarter that ended in Jun. 2025 was $9.55 Mil.
AXIM Biotechnologies's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.22 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AXIM Biotechnologies EV-to-EBIT Related Terms
AXIM Biotechnologies EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for AXIM Biotechnologies's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, AXIM Biotechnologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AXIM Biotechnologies EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AXIM Biotechnologies's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where AXIM Biotechnologies's EV-to-EBIT falls into.
AXIM Biotechnologies's current Enterprise Value is $8.85 Mil.
AXIM Biotechnologies's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.22 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AXIM Biotechnologies (AXIM) has a EV-to-EBIT of 40.25 as of Jul. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AXIM Biotechnologies and its competitors. According to the industry distribution chart, AXIM Biotechnologies ranks #285 out of 365 companies in the Biotechnology industry, placing it in the top 78.1%.
Is AXIM Biotechnologies' EV-to-EBIT too high?
AXIM Biotechnologies' current EV-to-EBIT is 40.25. The Biotechnology industry median EV-to-EBIT is 14.69. AXIM Biotechnologies' value of 40.25 is 174% above this industry median. Based on the distribution chart, AXIM Biotechnologies ranks #285 out of 365 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does AXIM Biotechnologies' EV-to-EBIT compare to ZVSA and HEPA?
According to the Biotechnology industry distribution chart, AXIM Biotechnologies ranks #285 out of 365 companies for EV-to-EBIT. This places AXIM Biotechnologies in the lower half of its industry. The industry median EV-to-EBIT is 14.69. AXIM Biotechnologies' value of 40.25 is 174% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.69, based on 365 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AXIM Biotechnologies's current EV-to-EBIT of 40.25 is 174% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AXIM Biotechnologies and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AXIM Biotechnologies's current EV-to-EBIT is 40.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AXIM Biotechnologies stock overvalued right now?
AXIM Biotechnologies (AXIM) has a current EV-to-EBIT of 40.25. The current EV-to-EBIT is 40.25 and 174% above the Biotechnology industry median of 14.69. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For AXIM Biotechnologies (AXIM), the current EV-to-EBIT is 40.25 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AXIM Biotechnologies Inc is a integrated research and development company and developer of diagnostic healthcare solutions serving to enhance the health of people. The company focuses on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AXIM has been successfully added to your 